$ANGO (AngioDynamics Inc.)

$ANGO {{ '2016-04-07T20:30:50+0000' | timeago}} • Announcement

$ANGO restated its FY16 net sales guidance to $347-350MM and adjusted EPS of $0.54-0.58. The company expects 4Q16 net sales to be in the range of $87-90MM and adjusted EPS of $0.14-0.18. $ANGO also reiterated its FY16 cash flow guidance of $30MM.

$ANGO {{ '2017-09-28T11:37:05+0000' | timeago}} • Announcement

For FY18, $ANGO expects its net sales to be in the range of about $352-359MM, and adjusted EPS to be about $0.64-0.68. Free cash flow is expected to be greater than $35MM.

$ANGO {{ '2017-09-28T11:33:15+0000' | timeago}} • Announcement

$ANGO slipped into a loss of $35,000 or $0.00 per share in 1Q18 from a profit of $1.3MM or $0.04 per share in 1Q17. The results were mainly impacted by the recall and voluntary market withdrawal of the Acculis Microwave Tissue Ablation System which was initiated in 4Q17. Net sales fell 3% YoY to $85.4MM. Adj. EPS was $0.12 per share for the period.

$ANGO {{ '2017-06-07T13:36:30+0000' | timeago}} • Announcement

$ANGO said the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Solero Microwave Tissue Ablation (MTA) System. The Solero MTA System and Accessories are indicated for the ablation of soft tissue during open procedures. The Solero MTA System is not intended for cardiac use.

$ANGO {{ '2017-03-30T12:57:22+0000' | timeago}} • Webcast

$ANGO said that R&D was lighter than expected in 2Q17 and 3Q17, because the company had taken a step back from its R&D process and have analyzed where it can win in the places where it wants to participate. Additionally, $ANGO took a fair amount of resources and redirected it towards Celero which reduced the R&D spend.

$ANGO {{ '2017-03-30T12:36:51+0000' | timeago}} • Webcast

$ANGO said that regarding the sales pipeline, there is no change but there is a bigger change in the R&D pipeline. The company added that the sales pipeline is similar to what it has been and $ANGO is now preparing with its sales strategies to be where it needs to be to support the new product launches.

$ANGO {{ '2017-03-30T12:24:38+0000' | timeago}} • Webcast

$ANGO stated that it is not increasing its free cash flow guidance currently as the company is anticipating an inventory build of approx. $5-6MM in 4Q17 to support the closure of Denmead, U.K and Manchester, Georgia facilities. Going forward, $ANGO is focused on improving the performance through R&D, managerial execution and operational excellence.

$ANGO {{ '2017-03-30T10:46:35+0000' | timeago}} • Announcement

$ANGO generated $14.4MM in operating cash flow and $14.0MM in free cash flow in 3Q17. As of February 28, 2017, cash and cash equivalents were $35.6MM and debt was $98.8MM.

$ANGO {{ '2017-03-30T10:46:08+0000' | timeago}} • Announcement

$ANGO saw net sales of its peripheral vascular segment fall 2.6% to $48.5MM in 3Q17. Vascular access net sales fell 4.8% to $23.7MM, while oncology/surgery net sales grew 7.4% to $13.0MM. Overall U.S. net sales were down 3% to $67.4MM.

$ANGO {{ '2017-03-30T10:37:49+0000' | timeago}} • Announcement

In 3Q17, $ANGO's net income surged by about four times to $2.9MM or $0.08 per share, from $0.6MM or $0.02 per share a year ago. The rise was driven by lower operating expenses, primarily from acquisition, restructuring and other items. Net sales for the quarter fell 2% to $85.6MM.

$ANGO {{ '2017-03-14T18:00:27+0000' | timeago}} • Announcement

Medical devices maker $ANGO received the CE Mark certification for the Solero Microwave Tissue Ablation (MTA) System. The Solero MTA System is used during open, laparoscopic or percutaneous procedures.

$ANGO {{ '2017-01-06T13:51:48+0000' | timeago}} • Webcast

$ANGO stated the company is going to have a longer term approach towards streamlining its operations and gaining efficiencies. The company added that this streamlining is not going to disable it from growing the revenue line.

$ANGO {{ '2017-01-06T13:20:41+0000' | timeago}} • Webcast

$ANGO's Peripheral Vascular franchise had $52.9MM in revenue in 2Q17, up 4% YoverY, and the company is now focusing on maintaining the business over the long term. In Vascular Access, revenue declined 6% YoverY to $23.6MM, while the decline was offset by growth in BioFlo Midline and Dialysis. The Oncology/Surgery franchise declined 6% YoverY.

$ANGO {{ '2017-01-06T13:15:58+0000' | timeago}} • Webcast

$ANGO stated that its cash flow performance during 2Q17 was ahead of expectations, generating $14.9MM in operating cash flow and $13.6MM in free cash flow. Additionally, the company ended 2Q17 with $35.7MM in cash and cash equivalents and had an outstanding debt of $116.5MM.

$ANGO {{ '2017-01-06T11:26:47+0000' | timeago}} • Announcement

For FY17, $ANGO's guidance remains unchanged, with net sales guidance in the range of $355-360MM. However, the company is increasing its FY17 adjusted EPS guidance from a range of $0.62-0.65 to a range of $0.65-0.67 and free cash flow guidance from greater than $30MM to greater than $35MM.

$ANGO {{ '2017-01-06T11:24:10+0000' | timeago}} • Announcement

$ANGO continued to see its 2Q17 results driven by the Peripheral Vascular franchise, enhanced by demand created by the Cook Medical angiographic catheter recall. Across the business, $ANGO also delivered strong performance in BioFlo Midline in the Vascular Access franchise, as well as increased utilization in NanoKnife within Oncology/Surgery.

$ANGO {{ '2017-01-06T11:20:02+0000' | timeago}} • Announcement

Medical device company $ANGO posted a 2Q17 net income of $13.73MM or $0.37 per diluted share, driven primarily by adjustments to contingent consideration and operational improvements, compared to a net loss of $0.33MM or loss per share of $0.01 per diluted share a year ago. $ANGO net sales for the quarter was flat YoverY at $89.03MM.

$ANGO {{ '2016-11-09T18:38:46+0000' | timeago}} • Announcement

$ANGO has appointed Eileen Auen and Jan Stern Reed to its BoD. Ms. Auen currently serves as the Lead Director for ICF International and Ms. Reed currently serves as a member of the BoD for Stepan Company.

$ANGO {{ '2016-10-05T13:10:41+0000' | timeago}} • Webcast

Jason Mills with Canaccord probes on why AngioVac is not gaining traction more quickly and how the company is looking to reinvigorate the growth of AngioVac. $ANGO said that in the past there was some extra product in the marketplace, so there was no bump up in sales. Over time, the company has to define its strategy better than it has before.

$ANGO {{ '2016-10-05T13:03:27+0000' | timeago}} • Webcast

Matt Mishan from KeyBanc asks about the sales and EPS performance drivers in 1Q17. $ANGO said the company is specifically thoughtful about where its dollars are spent. The company is also analyzing its headcount related to the performance in 1Q17 and if it is required to add some headcount or reorganize the company to a leaner cost structure.

$ANGO {{ '2016-10-05T12:35:47+0000' | timeago}} • Webcast

$ANGO's 1Q17 GM declined 70 BP YoverY, driven by pricing pressure and the mix of products sold. However, the company is confident of increasing GM across its operating businesses going forward. The company spent over $400,000 in CapEx in the quarter and at the end of 1Q17, $ANGO had $37.4MM in cash and cash equivalents and gross debt of $118.9MM.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
CORI (Corium International, Inc.)
Thursday, November 16 2017 - 10:00pm
TEAR (TearLab Corporation)
Monday, November 13 2017 - 9:30pm
ENSG (The Ensign Group, Inc.)
Thursday, November 9 2017 - 6:00pm
SRDX (SurModics, Inc.)
Wednesday, November 8 2017 - 1:30pm
PRSC (Providence Service Corp.)
Wednesday, November 8 2017 - 1:00pm
TBPH (Theravance Biopharma, Inc.)
Tuesday, November 7 2017 - 10:00pm
UEIC (Universal Electronics Inc.)
Thursday, November 2 2017 - 8:30pm
CERS (Cerus Corporation)
Thursday, November 2 2017 - 8:15pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
OSUR (OraSure Technologies, Inc.)
Wednesday, November 1 2017 - 9:00pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
OFIX (Orthofix International N.V.)
Monday, October 30 2017 - 8:30pm
ITGR (Integer Holdings Corporation)
Thursday, October 26 2017 - 9:00pm
TNDM (Tandem Diabetes Care, Inc.)
Thursday, October 26 2017 - 8:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
PLXS (Plexus Corp.)
Thursday, October 26 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, October 25 2017 - 12:30pm
NUVA (NuVasive, Inc.)
Tuesday, October 24 2017 - 8:30pm
ANGO (AngioDynamics Inc.)
Thursday, September 28 2017 - 12:00pm

AlphaGraphics you may like